Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo …

…, W McGee, K Reinhart, S Kljucar, S Souza… - Critical care …, 2004 - journals.lww.com
… PAF acetylhydrolase (PAF-AH) is a member of the phospholipase A2 family of enzymes (
27, 28 ). The extracellular form of PAF-AH is a secreted plasma protein that serves to inactivate …

Does linezolid inhibit its own metabolism?—population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients

N Plock, C Buerger, C Joukhadar, S Kljucar… - Drug metabolism and …, 2007 - ASPET
… In brief, population PK is a method that is able to analyze concentration-time data of
many individuals simultaneously. Moreover, overall variability can be characterized and …

Effect of severity of sepsis on tissue concentrations of linezolid

…, N Plock, S Kljucar, S Wuenscher… - Journal of …, 2008 - academic.oup.com
… technique which is capable of assessing the interstitial concentrations of antibiotics in
tissues. … The rationale of this study is based on previous data, clearly demonstrating that the …

Outbreaks of Staphylococcus aureus infections during treatment of late onset pneumonia with ciprofloxacin in a prospective, randomized study

…, J Timm, E v. Pritzbuer, M Heimesaat, S Kljucar - Intensive care …, 1998 - Springer
We carried out a prospective, randomized four-center study in nosocomial pneumonia to
evaluate the clinical and microbiological efficacy and safety of different treatment regimens in …

Efficacy and safety of higher-dose intravenous ciprofloxacin in severe hospital-acquired infections

S Kljucar, M Heimesaat, E von Pritzbuer, J Timm… - The American journal of …, 1989 - Elsevier
… The recommended oral dose of ciprofloxacin for severe hospital infections is 750 mg every
12 hours. Because the oral bioavailability of ciprofloxacin is 75 to 80 percent, we decided to …

Dose-finding investigations of intravenous ciprofloxacin in a pharmacodynamic model

A Bauernfeind, S Kljucar - Ciprofloxacin IV, Defining its Role in Serious …, 1994 - Springer
Major predictive parameters for the therapeutic efficacy of antibiotics are its minimal inhibitory
concentrations (MICs) against a broad spectrum of pathogens and the concentrations of …

The unstable thoracic wall: possibilities for treatment

B Friedrich, H Redeker, S Kljucar - Helvetica Chirurgica Acta, 1991 - europepmc.org
In the treatment of severe chest injuries with flail chest either positive-pressure mechanical
ventilation (and tracheostomy) is necessary or the surgical stabilisation of the chest wall by …

Ciprofloxacin in the treatment of hospital-acquired pneumonia: a surveillance study in 676 patients

S Kljucar, KL Rost, H Landen - Pneumologie (Stuttgart, Germany), 2002 - europepmc.org
Background Controlled clinical trials have shown efficacy of high-dose ciprofloxacin for
hospital-acquired (HAP) or nosocomial pneumonia. But it has yet to be demonstrated whether …

Capacitor-less, long-retention (> 400s) DRAM cell paving the way towards low-power and high-density monolithic 3D DRAM

…, A Chasin, MJ Van Setten, L Kljucar… - 2020 IEEE …, 2020 - ieeexplore.ieee.org
We report for the first time a fully 300-mm stacking-compatible capacitor-less DRAM cell with
>400s retention time by integrating two IGZO-TFTs in a 2T0C configuration. We optimize the …

28nm pitch single exposure patterning readiness by metal oxide resist on 0.33 NA EUV lithography

D De Simone, L Kljucar, P Das, R Blanc… - Extreme Ultraviolet …, 2021 - spiedigitallibrary.org
… it is more cost effective than 0.33NA EUV double patterning. In addition, we have conducted
a process feasibility study as P28 in single print is … exposure using Inpria’s MOx process on a …